Emcure Pharma shares to list on July 10: Key things to know before listing on NSE, BSE

Emcure Pharma IPO is all set to make market debut on July 10. The IPO subscription closed on July 5 with a strong demand from investors.

The pharma company's initial public offering (IPO) was subscribed 67.87 times, as the investors applied for a total of 92.99 crore shares compared to 1.37 crore shares.

The book-building issue is valued at ₹1,952.03 crore. The mainboard IPO comprises a fresh issue of 79 lakh shares amounting to ₹800 crore, and an offer-for-sale (OFS) component of 1.14 crore shares worth ₹1,152.03 crore.

After a successful subscription, the investors are waiting for the IPO allotment status, which is expected to be finalised on July 8. Shares of Emcure Pharmaceuticals Ltd are scheduled to be listed on the BSE and NSE on July 10.

Here’s a look at important details of the IPO ahead of the listing:

Emcure Pharmaceuticals IPO allotment status

The basis of share allotment for the Emcure Pharmaceuticals IPO is scheduled for July 8. Investors who participated in the IPO subscription can check their allotment status online through the BSE and NSE websites and register Link Intime India Pvt Ltd.

Steps to check the status on the BSE website:

• Visit the IPO share allotment status page on the BSE at https://www.bseindia.com/investors/appli_check.aspx
• Choose ‘equity’ as the issue type
• Select ‘Emcure Pharmaceuticals’ from the drop-down menu for ‘issue name’
• Enter your PAN or IPO application number and click ‘search’.

Steps to check Emcure Pharma IPO allotment on the registrar website:

• Go to the IPO registrar’s website using this link: https://www.linkintime.co.in/
• Choose the 'Public Issues' section
• Select ‘Emcure Pharma IPO’ from the issue name menu
• Type in any of these- PAN, IPO application number, DP/Client ID or bank account number and IFSC
• Click on the 'Submit' button

The investors can also check the IPO allotment status on the websites of IPO registrar Link Intime India and the NSE using PAN, application number and bank account details. However, it’s important to note that the applicants need to register on the NSE website to check the allotment status.

Emcure Pharmaceuticals IPO subscription

The Emcure Pharmaceuticals IPO saw strong interest from Qualified Institutional Buyers (QIBs), as the category was booked 195.83 times. The QIBs applied for over 73.68 crore shares against 37.62 lakh shares on offer. Non-institutional investors (NIIs) also showed strong interest, subscribing to their portion 48.32 times. The category received bids for 14.25 crore shares against 29.49 crore shares set aside for the category.

However, retail investors responded more modestly, subscribing their portion only 7.21 times. The retail investors applied for 4.96 crore shares compared to 68.82 lakh shares reserved for the category.

Emcure Pharma raises ₹582 crore from anchor investors

A day before the launch of its initial public offering (IPO), Pune-based Emcure Pharmaceuticals Ltd raised over ₹582 crore from anchor investors. The anchor book included names such as HDFC Mutual Fund, SBI Mutual Fund, ICICI Pru ICICI Pru MF, Goldman Sachs Asset Management, Morgan Stanley, Nomura, and Abu Dhabi Investment Authority.

What will Emcure Pharma do with IPO funds?

Emcure Pharmaceuticals aims to use the net proceeds from the IPO to repay or prepay outstanding borrowings and for general corporate purposes. Experts estimate the company's market capitalisation to be in the range of ₹19,000 crore post-listing.

About Emcure Pharmaceuticals Limited

Founded in 1981, Emcure Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products. These include pills, liquids, injectables, and specialized compounds such as chiral molecules, iron molecules, and cytotoxic substances. The company has 13 manufacturing facilities in India. As of September 30, 2023, Emcure Pharmaceuticals employed 552 scientists and operated five research facilities across India.

To know more about IPOs listing, schedule and upcoming IPOs, click here